Drug Use Following Genetic Testing Among Patients with Cancer

    Basic Details
    Date Posted
    Wednesday, May 10, 2017
    Status
    Complete
    Medical Product
    afatinib dimaleate
    BCR-ABL
    bosutinib
    BRAF
    BRCA
    cetuximab
    cobimetinib fumarate
    dabrafenib mesylate
    dasatinib
    erlotinib HCL
    estimated glomerular filtration rate (eGFR)
    gefitinib
    imatinib mesylate
    KRAS
    nilotinib HCL
    olaparib
    osimertinib mesylate
    panitumumab
    ponatinib HCL
    trametinib dimethyl sulfoxide
    vemurafenib
    Health Outcome(s)
    cancer
    Description

    This project contains three reports. Report 1 contains estimates of drug use among patients with a prior genetic test and/or relevant cancer diagnosis. Report 2 contains estimated distribution of baseline covariates among members receiving various genetic tests: KRAS, BRAF, EGFR, BCR-ABL, and BRCA. Report 3 contains estimates of drug initiation following genetic testing among patients with relevant cancers.The query was run against the Sentinel Distributed Database (SDD) for the time period of January 1, 2013 to December 31, 2015. The request was distributed to 14 Data Partners on June 17, 2016.

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2013 - December 31, 2015
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Sentinel Distributed Database (SDD)